tiprankstipranks
Trending News
More News >

Taysha Gene Therapies announces Part B trial design for TSHA-102

Taysha Gene Therapies (TSHA) announced details of its planned pivotal Part B trial design for TSHA-102 following written alignment from the FDA. Additionally, the company announced clinical data from Part A of the REVEAL Phase 1/2 adolescent/adult and pediatric trials evaluating TSHA-102 in Rett syndrome. The alignment reached with the FDA was supported by the company’s analysis of the International Rett Syndrome Foundation’s longitudinal Rett syndrome natural history study data, as well as clinical data from the ongoing REVEAL Phase 1/2 trials.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue